Physician Tests
Comprehensive Molecular Profiling for Cancer Therapy Selection
Whole Exome and Whole Transcriptome Sequencing, Plus Protein Analysis and Molecular AI
Caris performs artificial intelligence (AI)-enhanced comprehensive molecular profiling to help healthcare providers make more personalized treatment decisions for their patients. Caris’ industry-leading laboratories help improve the lives of thousands of patients each day through the analysis of DNA and RNA by whole exome and whole transcriptome sequencing (WES/WTS) in tissue or blood, plus immunohistochemistry (IHC) of key proteins in tissue specimens. Caris innovates AI-enabled techbio solutions to provide predictive algorithms that can further characterize certain tumors.
These deep molecular insights into a patient’s cancer help healthcare providers to:
- NAVIGATE among therapies with potential benefit.
- IDENTIFY therapies that may not have been considered.
- DETERMINE drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs).
- MATCH patients to clinical trials.
Simultaneous WES/WTS-based profiling with FDA-approved CDx indications for adult and pediatric patients, plus additional IHCs and other tests by tumor type.
USE:
Profiling for Therapy Selection & Additional Services
COVERAGE:
DNA, RNA, Proteins
INDICATION:
Solid Tumors
SPECIMEN:
Tissue
Simultaneous WES/WTS-based profiling with FDA-approved CDx indications for adult and pediatric patients.
USE:
Profiling for Therapy Selection & Additional Services
COVERAGE:
DNA, RNA
INDICATION:
Solid Tumors
SPECIMEN:
Tissue
Simultaneous WES/WTS-based profiling, plus additional IHCs and other tests by tumor type.
USE:
Profiling for Therapy Selection
COVERAGE:
DNA, RNA
INDICATION:
Solid Tumors
SPECIMEN:
Tissue
Blood-based WES and WTS of plasma and buffy coat (WBCs) to detect tumor-derived, incidental clonal hematopoiesis (CH) and incidental germline variants.
USE:
Profiling for Therapy Selection
COVERAGE:
DNA, RNA
INDICATION:
Solid Tumors
SPECIMEN:
Blood
Caris MI Clarity™ is a risk recurrence profiling tool designed to prognosticate long-term outcomes in early-stage breast cancer. The assay analyzes digitalized Hematoxylin and Eosin (H&E) whole slide images (WSIs) together with clinical inputs to generate probabilities of early distant recurrence (0–5 years) and late distant recurrence (5–15 years). These probabilities are subsequently stratified into categorical risk groups (e.g., low vs. high risk).
USE:
Profiling for early-stage breast cancer distant risk recurrence
COVERAGE:
DNA, RNA
INDICATION:
Breast Cancer
SPECIMEN:
FFPE Block or Unstained slides
Bone marrow or blood based WGS and WTS to detect clinically relevant single-nucleotide variants, short insertions and deletions in >70 genes with known relevance to hematological neoplasms.
USE:
Profiling for early-stage breast cancer distant risk recurrence
COVERAGE:
DNA, RNA
INDICATION:
Myeloid Malignancies
SPECIMEN:
Bone Marrow Aspirate and Whole Blood
Discover
More
Chemotherapy response predictor for first-line therapy sequencing:
- (either) FOLFOX+BV followed by FOLFIRI+BV
- (or) FOLFIRI+BV followed by FOLFOX+BV
Tumor of origin predictor
- Predicts or confirms likely tumor of origin
- Compares tumor molecular characteristics against 90+ known tumor types in the Caris database